Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The trial is an open-label, multicenter, prospective, randomized trial in 2 parallel groups,
evaluating at W48 the non inferiority of antiretroviral dual therapy taken 4 consecutive days
per week versus antiretroviral dual therapy 7/7 days per week in HIV-1 infected patients with
controlled viral load under antiretroviral dual therapy.